Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
Xu Yang, Ying Hu, Keyan Yang, Dongxu Wang, Jianzhen Lin, Junyu Long, Fucun Xie, Jinzhu Mao, Jin Bian, Mei Guan, Jie Pan, Li Huo, Ke Hu, Xiaobo Yang, Yilei Mao, Xinting Sang, Jiao Zhang, Xi Wang, Henghui Zhang, Haitao Zhao, Xu Yang, Ying Hu, Keyan Yang, Dongxu Wang, Jianzhen Lin, Junyu Long, Fucun Xie, Jinzhu Mao, Jin Bian, Mei Guan, Jie Pan, Li Huo, Ke Hu, Xiaobo Yang, Yilei Mao, Xinting Sang, Jiao Zhang, Xi Wang, Henghui Zhang, Haitao Zhao
Abstract
Background: This study was designed to screen potential biomarkers in plasma cell-free DNA (cfDNA) for predicting the clinical outcome of immune checkpoint inhibitor (ICI)-based therapy in advanced hepatobiliary cancers.
Methods: Three cohorts including 187 patients with hepatobiliary cancers were recruited from clinical trials at the Peking Union Medical College Hospital. Forty-three patients received combination therapy of programmed cell death protein 1 (PD-1) inhibitor with lenvatinib (ICI cohort 1), 108 patients received ICI-based therapy (ICI cohort 2) and 36 patients received non-ICI therapy (non-ICI cohort). The plasma cfDNA and blood cell DNA mutation profiles were assessed to identify efficacy biomarkers by a cancer gene-targeted next-generation sequencing panel.
Results: Based on the copy number variations (CNVs) in plasma cfDNA, the CNV risk score model was constructed to predict survival by using the least absolute shrinkage and selection operator Cox regression methods. The results of the two independent ICI-based therapy cohorts showed that patients with lower CNV risk scores had longer overall survival (OS) and progression-free survival (PFS) than those with high CNV risk scores (log-rank p<0.01). In the non-ICI cohort, the CNV risk score was not associated with PFS or OS. Furthermore, the results indicated that 53% of patients with low CNV risk scores achieved durable clinical benefit; in contrast, 88% of patients with high CNV risk scores could not benefit from combination therapy (p<0.05).
Conclusions: The CNVs in plasma cfDNA could predict the clinical outcome of the combination therapy of PD-1 inhibitor with lenvatinib and other ICI-based therapies in hepatobiliary cancers.
Keywords: immunotherapy; liver neoplasms; tumor biomarkers.
Conflict of interest statement
Competing interests: None declared.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Figures
References
- Benson AB, D'Angelica MI, Abbott DE, et al. . Guidelines insights: hepatobiliary cancers, version 2.2019. J Natl Compr Canc Netw 2019;17:302–10. 10.6004/jnccn.2019.0019
- Lin J, Shi J, Guo H, et al. . Alterations in DNA damage repair genes in primary liver cancer. Clin Cancer Res 2019;25:4701–11. 10.1158/1078-0432.CCR-19-0127
- Sangro B, Park J, Finn R, et al. . LBA-3 CheckMate 459: long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. Ann Oncol 2020;31:S241–2. 10.1016/j.annonc.2020.04.078
- Finn RS, Ryoo B-Y, Merle P, et al. . Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:Jco1901307. 10.1200/JCO.19.01307
- Kim RD, Chung V, Alese OB, et al. . A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 2020;6:888–8. 10.1001/jamaoncol.2020.0930
- Kudo M, Finn RS, Qin S, et al. . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–73. 10.1016/S0140-6736(18)30207-1
- Ikeda M, Sasaki T, Morizane C, et al. . A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. Ann Oncol 2017;28:v246. 10.1093/annonc/mdx369.106
- Wang D, Lin J, Yang X, et al. . Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol 2019;12:42. 10.1186/s13045-019-0730-9
- Yoo C, Oh D-Y, Choi HJ, et al. . Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer 2020;8:e000564. 10.1136/jitc-2020-000564
- Finn RS, Qin S, Ikeda M, et al. . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–905. 10.1056/NEJMoa1915745
- Kudo M, Ikeda M, Motomura K, et al. . A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (PTS) with unresectable hepatocellular carcinoma (uHCC): study 117. JCO 2020;38:513. 10.1200/JCO.2020.38.4_suppl.513
- Lin J, Yang X, Zhao S, et al. . Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma. Ann Oncol 2019;30:v517. 10.1093/annonc/mdz253.097
- Lin J, Yang X, Long J, et al. . Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 2020;9:414–24. 10.21037/hbsn-20-338
- Finn RS, Ikeda M, Zhu AX, et al. . Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020;38:2960–70. 10.1200/JCO.20.00808
- Sangro B, Melero I, Wadhawan S, et al. . Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol 2020;73:1460–9. 10.1016/j.jhep.2020.07.026
- Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, et al. . Early detection of metastatic relapse and monitoring of therapeutic efficacy by Ultra-Deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019;37:1547–57. 10.1200/JCO.18.02052
- Cai J, Chen L, Zhang Z, et al. . Genome-Wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut 2019;68:2195–205. 10.1136/gutjnl-2019-318882
- Cristiano S, Leal A, Phallen J, et al. . Genome-Wide cell-free DNA fragmentation in patients with cancer. Nature 2019;570:385–9. 10.1038/s41586-019-1272-6
- Cabel L, Proudhon C, Romano E, et al. . Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol 2018;15:639–50. 10.1038/s41571-018-0074-3
- Lipson EJ, Velculescu VE, Pritchard TS, et al. . Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer 2014;2:42. 10.1186/s40425-014-0042-0
- Giroux Leprieur E, Hélias-Rodzewicz Z, Takam Kamga P, et al. . Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. J Immunother Cancer 2020;8:e000527. 10.1136/jitc-2020-000527
- Forschner A, Battke F, Hadaschik D, et al. . Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. J Immunother Cancer 2019;7:180. 10.1186/s40425-019-0659-0
- Heimbach JK, Kulik LM, Finn RS, et al. . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358–80. 10.1002/hep.29086
- Zhou J, Sun H-C, Wang Z, et al. . Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer 2018;7:235–60. 10.1159/000488035
- Schwartz LH, Litière S, de Vries E, et al. . RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 2016;62:132–7. 10.1016/j.ejca.2016.03.081
- Quispel-Janssen J, van der Noort V, de Vries JF, et al. . Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol 2018;13:1569–76. 10.1016/j.jtho.2018.05.038
- Sasaki K, Morioka D, Conci S, et al. . The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors. Ann Surg 2018;267:132–41. 10.1097/SLA.0000000000002064
- Vitale A, Lai Q, Farinati F, et al. . Utility of tumor burden score to stratify prognosis of patients with hepatocellular cancer: results of 4759 cases from Study Group. J Gastrointest Surg 2018;22:859–71. 10.1007/s11605-018-3688-y
- Sanchez-Vega F, Mina M, Armenia J, et al. . Oncogenic signaling pathways in the cancer genome atlas. Cell 2018;173:321–37. 10.1016/j.cell.2018.03.035
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74. 10.1016/j.cell.2011.02.013
- Davoli T, Uno H, Wooten EC, et al. . Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017;355(6322) (published Online First: 2017/01/21).
- Roh W, Chen P-L, Reuben A, et al. . Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 2017;9:eaah3560. 10.1126/scitranslmed.aah3560
- Liu L, Bai X, Wang J, et al. . Combination of TMB and CNA Stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. Clin Cancer Res 2019;25:7413–23. 10.1158/1078-0432.CCR-19-0558
- Lu Z, Chen H, Li S, et al. . Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. J Immunother Cancer 2020;8:e000374. 10.1136/jitc-2019-000374
- Bassaganyas L, Pinyol R, Esteban-Fabró R, et al. . Copy-Number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma. Clin Cancer Res 2020;26:6350–61. 10.1158/1078-0432.CCR-20-1497
- Weiss GJ, Beck J, Braun DP, et al. . Tumor cell-free DNA copy number instability predicts therapeutic response to immunotherapy. Clin Cancer Res 2017;23:5074–81. 10.1158/1078-0432.CCR-17-0231
- Jensen TJ, Goodman AM, Kato S, et al. . Genome-Wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients. Mol Cancer Ther 2019;18:448–58. 10.1158/1535-7163.MCT-18-0535
Source: PubMed